Roche, Teva square off in patent fight

To brand-name drug makers, Teva Pharmaceuticals is something of a Big Bad Wolf: I'll huff and I'll puff and I'll blow your patents down!

Of course, Big Pharma is no defenseless little pig--just witness Novartis' successful (at least for now) shutdown of Teva's copycat Famvir. Now, Roche is suing Teva for producing a generic version of its osteoporosis treatment Boniva, whose patents begin to expire in 2012. The drug racked up $314 million in sales just in the first half of 2007, so it's well worth the legal expense. Roche is asking a New Jersey court to keep Teva's generic version off the U.S. market.

- read the article from the International Herald Tribune

Related Articles:
Novartis wins round on Famvir knockoff. Report
Injectable Boniva approved. Report
Researchers tout once-monthly Boniva data. Report
Roche, GSK outline head-to-head trial of Boniva, Fosamax. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.